Robert W. Baird Issues Positive Forecast for Agenus (NASDAQ:AGEN) Stock Price

Agenus (NASDAQ:AGEN - Free Report) had its target price boosted by Robert W. Baird from $3.00 to $4.00 in a report released on Tuesday,Benzinga reports. Robert W. Baird currently has a neutral rating on the biotechnology company's stock.

AGEN has been the subject of several other research reports. StockNews.com raised shares of Agenus from a "sell" rating to a "hold" rating in a research report on Friday, March 21st. HC Wainwright reissued a "neutral" rating on shares of Agenus in a research report on Wednesday, April 30th. Finally, B. Riley reissued a "buy" rating on shares of Agenus in a research report on Monday, April 21st. Six analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat, Agenus currently has a consensus rating of "Hold" and a consensus target price of $9.00.

Agenus Price Performance

Shares of NASDAQ:AGEN traded up $0.10 during mid-day trading on Tuesday, reaching $3.48. 826,490 shares of the company were exchanged, compared to its average volume of 588,596. The firm has a market cap of $95.41 million, a price-to-earnings ratio of -0.31 and a beta of 1.48. The firm's 50-day simple moving average is $2.21 and its 200 day simple moving average is $2.91. Agenus has a 1 year low of $1.38 and a 1 year high of $19.69.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share for the quarter, topping analysts' consensus estimates of ($1.61) by $0.58. The company had revenue of $24.07 million for the quarter, compared to analysts' expectations of $26.38 million. On average, research analysts forecast that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agenus

A number of hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC raised its holdings in shares of Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company's stock valued at $664,000 after purchasing an additional 427,604 shares in the last quarter. Siren L.L.C. acquired a new stake in shares of Agenus in the 1st quarter valued at $752,000. Invesco Ltd. acquired a new stake in shares of Agenus in the 1st quarter valued at $88,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Agenus by 32.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 63,685 shares of the biotechnology company's stock valued at $96,000 after purchasing an additional 15,731 shares in the last quarter. Finally, Apollon Wealth Management LLC raised its holdings in shares of Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 5,000 shares in the last quarter. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.